Trials / Completed
CompletedNCT06051357
Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
An Multicenter, Randomized, Open-label Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, open-label phase II clinical trial. A total of 24 patients with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy were included. Subjects were treated with HRS-5965 for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-5965 tablets | HRS-5965 tablets for 12 weeks |
Timeline
- Start date
- 2023-11-15
- Primary completion
- 2024-03-25
- Completion
- 2024-03-25
- First posted
- 2023-09-22
- Last updated
- 2024-10-15
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06051357. Inclusion in this directory is not an endorsement.